# Melanotan II Pharmacology: A Non-Selective Cyclic Melanocortin Agonist at MC1R, MC3R, and MC4R

> A mechanistic analysis of Melanotan II (MT-II), a lactam-bridged cyclic heptapeptide alpha-MSH analog, covering non-selective melanocortin receptor agonism (MC1R tanning, MC3R/MC4R sexual function and appetite), phase I tanning and erection data, the bremelanotide (PT-141) lineage, afamelanotide contrast, and eruptive nevi safety signals.

Source: https://peptpedia.org/research/melanotan-ii-melanocortin-receptor-pharmacology | Published: 2026-07-18 | Last updated: 2026-07-18

## Direct Answer

Melanotan II is a synthetic lactam-bridged cyclic heptapeptide analog of α-MSH(4-10) that non-selectively activates melanocortin receptors. MC1R activation on melanocytes drives eumelanin synthesis and tanning; MC3R/MC4R activation in the hypothalamus produces pro-erectile and anorexigenic effects. Its unapproved status and case reports of eruptive atypical nevi define a significant unresolved safety profile.

## Key Data

| Parameter | Value | Note |
| --- | --- | --- |
| Structure | Cyclic heptapeptide lactam; Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂ (α-MSH4-10 core) |  |
| Receptor Profile | Non-selective melanocortin agonist (MC1R, MC3R, MC4R; also MC5R) |  |
| Molecular Weight | 1,024 Da |  |
| Phase I Exposure | 0.01–0.03 mg/kg SC (Dorr 1996 pilot) | Tanning after as few as 5 low doses; spontaneous erections and a stretching-yawning complex observed |
| Regulatory Status | Unapproved research compound; not authorized in US/EU |  |

## Structure: A Lactam-Bridged α-MSH(4-10) Core

Melanotan II (MT-II) is a synthetic analog of α-melanocyte-stimulating hormone built on the hormone's minimal active fragment. Native α-MSH is a linear 13-amino acid peptide (Ac-Ser¹-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val¹³-NH₂) whose melanotropic and behavioral activity maps to the central **His-Phe-Arg-Trp** message sequence. Structure-activity work in the Hruby and Hadley laboratories showed that truncating the peptide to residues 4-10 and imposing conformational constraint could dramatically increase potency. MT-II embodies both strategies: it is a **cyclic heptapeptide** with the sequence Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂, cyclized by an intramolecular **lactam bridge between the Asp⁵ and Lys¹⁰ side chains**.

Three engineering features account for its pharmacology. Norleucine at position 4 replaces methionine, eliminating oxidation-sensitive sulfur chemistry. D-phenylalanine at position 7 — the same substitution that made Melanotan I ([Nle⁴, D-Phe⁷]α-MSH) superpotent — stabilizes the bioactive conformation and resists proteolysis. The lactam bridge locks the message sequence into a turn conformation favored by melanocortin receptors, yielding what Dorr and colleagues (1996) characterized as a "superpotent" melanotropic peptide in vitro before its first human exposure.

## Receptor Pharmacology: Non-Selective Melanocortin Agonism

The melanocortin receptor family comprises five Gαs-coupled GPCRs (MC1R–MC5R) with distinct tissue distributions and physiological roles. MT-II is a **non-selective agonist** across MC1R, MC3R, MC4R, and MC5R, and its entire effect profile — desired and undesired — follows from that promiscuity:

- **MC1R (melanocytes):** Gαs/cAMP/PKA signaling upregulates microphthalmia-associated transcription factor (MITF) and tyrosinase, switching melanogenesis toward brown-black eumelanin. This is the tanning pathway and the peptide's original design target.

- **MC2R (adrenal cortex):** The ACTH-selective receptor; not meaningfully engaged by α-MSH analogs, which is why melanotans do not produce steroidogenic effects.

- **MC3R and MC4R (central nervous system):** Expressed in the hypothalamus and limbic system, these receptors govern energy homeostasis and sexual function. Molinoff and colleagues (2003) identified MC3R/MC4R agonism — expressed primarily in the CNS — as the mechanism behind the pro-erectile activity of the related analog PT-141, with hypothalamic c-Fos activation as the functional signature.

- **MC5R (exocrine glands):** Widely expressed in peripheral secretory tissue; its contribution to MT-II's effect profile is less well defined.

Because MC1R drives pigmentation while MC3R/MC4R drive sexual and appetite effects, a non-selective agonist cannot tan without also pressing the other switches. Every clinical observation of MT-II — pigmentation, spontaneous erections, yawning, nausea, reduced food intake — is a receptor-subtype readout of this single pharmacological fact.

## Human Evidence: The Dorr Phase I Studies

The first human data on MT-II came from a pilot phase I study by Dorr and colleagues (1996) in three normal male volunteers. Subcutaneous injections were given daily on weekdays for two consecutive weeks, beginning at 0.01 mg/kg with escalation to 0.025–0.03 mg/kg. Two findings defined the compound's subsequent trajectory. First, **tanning activity**: two subjects showed increased pigmentation of the face, upper body, and buttocks — measurable by quantitative reflectance — one week after dosing ended, demonstrating tanning with as few as five low alternate-day doses. Second, **sexual effects**: a stretching-and-yawning complex correlated with the onset of spontaneous penile erections, experienced intermittently for 1–5 hours after dosing in a dose-dependent fashion. Mild nausea occurred at most dose levels, and the 0.03 mg/kg dose produced WHO Grade II somnolence and fatigue in one subject, setting 0.025 mg/kg as the recommended single dose for further phase I work.

The erection observation — unexpected in a tanning program — became the proof-of-concept that redirected melanocortin chemistry toward sexual medicine. As the existing Peptpedia analysis of bremelanotide describes, researchers working on Melanotan II isolated sexual function as a distinct research endpoint, leading to the development of PT-141 as an analog optimized for that indication with a reduced melanogenic profile relative to MT-II.

## The PT-141 (Bremelanotide) Lineage

Bremelanotide (PT-141) emerged directly from the MT-II development program as the C-terminal carboxylic acid derivative of the same cyclic heptapeptide scaffold. Molinoff and colleagues (2003) characterized its pharmacology as an agonist at melanocortin receptors including **MC3R and MC4R**, which are expressed primarily in the central nervous system. Systemic PT-141 administration produced penile erections in rats and non-human primates, activated hypothalamic neurons (c-Fos immunoreactivity), and — in a striking neuroanatomical correlation — the same hypothalamic region takes up pseudorabies virus injected into the rat corpus cavernosum, mapping a defined brain-to-penis circuit for melanocortin-mediated erection.

In humans, intranasal PT-141 produced rapid, dose-dependent increases in erectile activity in both healthy men and patients with erectile dysfunction. The mechanistic contrast with PDE5 inhibitors is fundamental: rather than amplifying a peripheral vascular signal, melanocortin agonists initiate the erectile response centrally at the hypothalamic level. Bremelanotide was ultimately approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women — the only melanocortin-pathway drug derived from the MT-II lineage to reach the US market, and the clearest demonstration that MC3R/MC4R pharmacology could be separated from MC1R tanning as a therapeutic endpoint.

## MC4R and Metabolic Signaling: Appetite and Insulin Sensitivity

Central MC4R is the principal relay of the leptin-melanocortin appetite circuit: α-MSH released from POMC neurons activates MC4R to suppress food intake, while the endogenous antagonist agouti-related peptide (AgRP) opposes it. As an MC4R agonist, MT-II predictably engages this axis. Banno and colleagues (2004) administered MT-II subcutaneously via osmotic minipumps to OLETF rats — a model of obesity with insulin resistance — and observed decreased food intake and body weight as expected. The more informative result was metabolic: MT-II-treated rats showed **greater insulin sensitivity than both ad libitum-fed and pair-fed controls** in insulin tolerance tests on day 9, and significantly lower glucose values in glucose tolerance tests on days 11 and 23.

The pair-fed comparison matters because it separates receptor pharmacology from the secondary effects of eating less: MT-II improved insulin sensitivity beyond what matched caloric restriction achieved, indicating that central melanocortin tone directly modulates peripheral glucose handling. This experiment is frequently cited to illustrate why MC4R remains one of the most actively pursued — and so far therapeutically difficult — targets in obesity pharmacology, and it explains the appetite suppression consistently reported with non-selective melanotan use.

## Safety Signals and the Afamelanotide Contrast

The safety literature on MT-II is dominated by melanocytic proliferation reports — mechanistically predictable consequences of forcing MC1R signaling in melanocytes and nevomelanocytes. Cardones and Grichnik (2009) described a 40-year-old man with a history of melanoma and multiple dysplastic nevi who self-administered synthetic α-MSH analog (melanotan) and developed crops of new pigmented nevi, many with atypical clinical and histopathological features; pre-existing nevi darkened and acquired growth features, then progressively regressed after discontinuation. Reid and colleagues (2013) reported a patient who developed multiple new-onset atypical naevi within one week of just two Melanotan injections purchased as a "tanning jab." Their conclusion that synthetic α-MSH peptides can drive proliferation of neoplastic melanocytic cells in predisposed patients frames the central unresolved risk: MC1R agonism is mitogenic signaling delivered to exactly the cell lineage from which melanoma arises, and MT-II is distributed through unregulated internet and tanning-salon channels without pharmaceutical quality control.

The contrast case is **afamelanotide** (Melanotan I, [Nle⁴,D-Phe⁷]α-MSH) — the linear, full-length 13-amino acid analog from the same research lineage. Dorr and colleagues (2004) showed in three phase 1 trials that afamelanotide combined safely with UV-B or sunlight, acting synergistically in the tanning response: 3 of 4 subjects tanned at 0.08 mg/kg/day, irradiated sites showed 47% fewer sunburn cells, and tans persisted at least three weeks longer than sunlight-only controls with only minor toxicity (nausea, transient flushing). Kim and Garnock-Jones (2016) reviewed the compound's subsequent approval in the EU as SCENESSE — a first-in-class MC1R agonist given as a 16 mg biodegradable subcutaneous implant for preventing phototoxicity in erythropoietic protoporphyria, with phase III evidence of improved light tolerance and no drug-related serious adverse events. The two molecules thus illustrate divergent fates of melanocortin chemistry: a linear, MC1R-focused analog advanced through regulated trials to approval for a defined medical indication, while the more potent, non-selective cyclic analog remains an unapproved gray-market compound with accumulating dermatological case-report signals.

## Frequently Asked Questions

### Which melanocortin receptors does Melanotan II activate?

MT-II is a non-selective agonist at MC1R, MC3R, MC4R, and MC5R. MC1R activation on melanocytes produces eumelanin synthesis and tanning; MC3R/MC4R activation in the hypothalamus mediates pro-erectile effects and appetite suppression; MC5R (exocrine glands) is less characterized. It does not meaningfully engage MC2R, the ACTH-selective adrenal receptor, so it lacks steroidogenic effects.

### How is Melanotan II different from Melanotan I (afamelanotide)?

Afamelanotide is a linear full-length 13-amino acid α-MSH analog ([Nle⁴,D-Phe⁷]α-MSH) with activity focused on MC1R-mediated pigmentation; it completed regulated clinical development and is approved in the EU as a 16 mg implant for erythropoietic protoporphyria. MT-II is a shorter cyclic heptapeptide (α-MSH4-10 lactam) that is more potent but non-selective, hitting MC3R/MC4R (sexual function, appetite) as well as MC1R — and it has never received regulatory approval anywhere.

### What is the relationship between Melanotan II and PT-141 (bremelanotide)?

Bremelanotide is the C-terminal carboxylic acid derivative of MT-II's cyclic heptapeptide scaffold, developed from the same research program after phase I subjects experienced spontaneous erections. It acts primarily at central MC3R/MC4R receptors to initiate sexual responses at the hypothalamic level, with a reduced melanogenic (MC1R) profile compared to MT-II. It became the lineage's only US-approved drug (Vyleesi) for hypoactive sexual desire disorder.

### Why are there safety concerns about Melanotan II and moles?

MC1R agonism is a mitogenic signal to melanocytes and nevomelanocytes. Published case reports document eruptive atypical nevi after Melanotan use — including in a patient with prior melanoma whose new and pre-existing nevi showed atypical features that regressed after stopping, and a patient who developed multiple atypical naevi within a week of two injections. Combined with unregulated gray-market supply and unknown product purity, dermatology literature treats MT-II as a plausible melanoma risk in predisposed individuals.

## References

1. Dorr RT, Lines R, Levine N, et al.. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." *Life Sciences* (1996). [PMID 8637402](https://pubmed.ncbi.nlm.nih.gov/8637402/) | [doi:10.1016/0024-3205(96)00160-9](https://doi.org/10.1016/0024-3205(96)00160-9) — First-in-human pilot study (3 male volunteers, 0.01–0.03 mg/kg SC) documenting tanning after as few as five low alternate-day doses, plus dose-dependent spontaneous erections preceded by a stretching-yawning complex, mild nausea, and somnolence at the highest dose — defining both the tanning and sexual-function trajectories of MT-II research.
2. Molinoff PB, Shadiack AM, Earle D, et al.. "PT-141: a melanocortin agonist for the treatment of sexual dysfunction." *Annals of the New York Academy of Sciences* (2003). [PMID 12851303](https://pubmed.ncbi.nlm.nih.gov/12851303/) | [doi:10.1111/j.1749-6632.2003.tb03167.x](https://doi.org/10.1111/j.1749-6632.2003.tb03167.x) — Characterizes the MT-II-derived analog PT-141 as a centrally acting MC3R/MC4R agonist: erections in rats and primates, hypothalamic c-Fos activation mapping to the corpus-cavernosum-connected circuit, and rapid dose-dependent erectile responses in normal men and ED patients.
3. Banno R, Arima H, Sato I, et al.. "The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats." *Peptides* (2004). [PMID 15350695](https://pubmed.ncbi.nlm.nih.gov/15350695/) | [doi:10.1016/j.peptides.2004.05.007](https://doi.org/10.1016/j.peptides.2004.05.007) — Continuous subcutaneous MT-II in obese insulin-resistant rats reduced food intake and body weight and improved insulin sensitivity beyond pair-fed controls, demonstrating that central melanocortin (MC4R) activation modulates peripheral glucose handling independently of reduced caloric intake.
4. Cardones AR, Grichnik JM. "alpha-Melanocyte-stimulating hormone-induced eruptive nevi." *Archives of Dermatology* (2009). [PMID 19380666](https://pubmed.ncbi.nlm.nih.gov/19380666/) | [doi:10.1001/archdermatol.2008.623](https://doi.org/10.1001/archdermatol.2008.623) — Case report of a man with prior melanoma and dysplastic nevi who developed eruptive, histopathologically atypical nevi after self-administering synthetic α-MSH analog, with regression after discontinuation — evidence that melanocortin agonists can drive proliferation of neoplastic melanocytic cells in predisposed patients.
5. Reid C, Fitzgerald T, Fabre A, et al.. "Atypical melanocytic naevi following melanotan injection." *Irish Medical Journal* (2013). [PMID 23914578](https://pubmed.ncbi.nlm.nih.gov/23914578/) — Case report of multiple new-onset atypical naevi appearing within one week of two Melanotan injections obtained from unregulated 'tanning jab' channels, highlighting the risk of stimulating dysplastic naevi or melanoma with unsupervised use.
6. Dorr RT, Ertl G, Levine N, et al.. "Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers." *Archives of Dermatology* (2004). [PMID 15262693](https://pubmed.ncbi.nlm.nih.gov/15262693/) | [doi:10.1001/archderm.140.7.827](https://doi.org/10.1001/archderm.140.7.827) — Three phase 1 trials of Melanotan I (afamelanotide) combined with UV-B or sunlight: tanning synergy with 47% fewer sunburn cells at irradiated sites, longer-lasting tans than sunlight alone, and only minor toxicity — the regulated clinical pathway of the linear MT-I analog.
7. Kim ES, Garnock-Jones KP. "Afamelanotide: A Review in Erythropoietic Protoporphyria." *American Journal of Clinical Dermatology* (2016). [PMID 26979527](https://pubmed.ncbi.nlm.nih.gov/26979527/) | [doi:10.1007/s40257-016-0184-6](https://doi.org/10.1007/s40257-016-0184-6) — Review of afamelanotide (SCENESSE), the first-in-class MC1R agonist approved in the EU as a 16 mg subcutaneous implant for EPP phototoxicity prevention, with phase III evidence of improved light tolerance and no drug-related serious adverse events — the regulatory contrast to unapproved MT-II.

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org